01Purpose and principlesWhat the treatment does and how it fits into care.
Many intracranial tumours disrupt the blood–brain barrier and produce extracellular, predominantly white-matter vasogenic oedema. This can worsen headache, focal deficit, seizure tendency and intracranial pressure. Dexamethasone is favoured because of potent glucocorticoid activity and relatively little mineralocorticoid effect. Clinical improvement may occur before any tumour-directed therapy has acted, but that response is symptomatic and temporary.
The indication matters more than the scan label. Corticosteroids are reasonable when neurological or pressure symptoms are caused by oedema, particularly while surgery, radiotherapy or systemic treatment is being organised. They should not be started reflexively for every contrast-enhancing tumour in an asymptomatic person: harm rises with dose and duration, and steroids can obscure infection, worsen diabetes and mood, cause myopathy, and complicate diagnostic reasoning. In possible primary CNS lymphoma, specialist advice is especially important because glucocorticoids may reduce diagnostic tissue yield.
Dose evidence is population-specific. The Congress of Neurological Surgeons guideline for adults with metastatic brain tumours recommends considering 4–8 mg/day dexamethasone for mild symptoms related to mass effect and higher doses such as 16 mg/day for moderate or severe symptoms, with tapering as rapidly as clinically tolerated. A current UK 4 mg-tablet SmPC gives a product-specific oral cerebral-oedema range of 6–16 mg/day, up to 24 mg/day, divided three or four times. These are not interchangeable universal targets: the prescriber follows the applicable product, tumour context, local neuroscience protocol and clinical response.
Steroid withdrawal is an active part of treatment. Once definitive therapy controls the cause and neurological status permits, reduce toward the lowest effective dose and stop as promptly as tolerated. Abrupt cessation after substantial or prolonged exposure risks adrenal insufficiency; too-fast reduction may uncover recurrent oedema. A new deficit during taper therefore needs clinical assessment rather than automatic indefinite re-escalation. Pituitary apoplexy is a separate emergency: there, hydrocortisone replaces cortisol in adults meeting haemodynamic, consciousness or severe visual criteria.
Key points
- Dexamethasone reduces vasogenic oedema and offers temporary symptom relief; it does not treat the tumour, replace surgery or radiotherapy, or improve every asymptomatic scan abnormality.
- Treat the patient, not the MRI: use steroids when neurological or pressure symptoms are attributable to tumour-related oedema, and use the lowest effective dose for the shortest feasible duration.
- Adult brain-metastasis guidance supports 4–8 mg/day dexamethasone for mild mass-effect symptoms and consideration of about 16 mg/day or more for severe symptoms, then taper as rapidly as clinically tolerated; do not generalise this evidence to children or every primary tumour.
- A current product-specific 4 mg-tablet SmPC licenses cerebral oedema only when intracranial-pressure symptoms are CT-evidenced and gives 6–16 mg/day orally, up to 24 mg/day, in divided doses; specialist protocols and individual response determine the regimen.
- Monitor neurological response, glucose, infection, mood, sleep, proximal strength, blood pressure and gastrointestinal risk; longer exposure adds adrenal suppression, osteoporosis, myopathy and opportunistic infection.
- Pituitary apoplexy with haemodynamic, consciousness or severe visual compromise requires hydrocortisone adrenal replacement under its own emergency guidance; dexamethasone for vasogenic oedema is not a substitute.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Progressive focal deficit, headache, vomiting or reduced function with white-matter oedema and mass effect may respond to dexamethasone. Correlate symptom anatomy and tempo with imaging rather than treating oedema volume alone.
Falling consciousness, pupil change, abnormal breathing, rapid motor decline or hydrocephalus requires emergency source control. Dexamethasone can accompany appropriate care but must not delay surgery, CSF diversion or haemorrhage management.
Insomnia, anxiety and irritability are common; mania, psychosis, severe depression and delirium can be dangerous. Distinguish medication timing from tumour, seizure, infection and metabolic causes.
Check thirst, polyuria, infection, dyspepsia and proximal weakness. Steroid myopathy may mimic tumour progression through loss of mobility without a new focal pattern.
Fatigue, hypotension, nausea or diffuse weakness after prolonged therapy suggests adrenal suppression, while return of the original focal deficit suggests recurrent oedema or tumour progression. Both need review.
Acute headache, ophthalmoplegia, visual loss and hypotension with a sellar lesion indicate apoplexy and possible ACTH failure. Use the hydrocortisone emergency pathway rather than a generic cerebral-oedema schedule.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Neurological baseline and serial examinationFirst step - Why
- Measure whether symptoms attributed to oedema improve and detect deterioration requiring urgent source control.
- Interpretation and limitations
- Record consciousness, pupils, focal deficits, gait and function before treatment. Lack of improvement or new decline prompts imaging and diagnostic review rather than dose escalation by habit.
- 02
CT or contrast-enhanced MRI brain - Why
- Confirm tumour, oedema, haemorrhage, hydrocephalus and mass effect and guide definitive treatment.
- Interpretation and limitations
- The selected SmPC indication is CT-evidenced pressure symptoms from cerebral oedema. MRI better characterises tumour and oedema; imaging severity alone does not mandate steroids in an asymptomatic person.
- 03
Capillary and laboratory glucose - Why
- Detect steroid-induced hyperglycaemia and guide diabetic treatment adjustment.
- Interpretation and limitations
- Check baseline risk and repeat according to dose, symptoms and diabetes status. Dexamethasone can reveal or substantially worsen hyperglycaemia.
- 04
Infection and gastrointestinal risk assessment - Why
- Identify active infection, immunosuppression, ulcer risk and interacting medicines before and during therapy.
- Interpretation and limitations
- Steroids may suppress fever and inflammatory signs. Gastroprotection is individualised rather than automatic, with particular attention to prior ulcer, anticoagulation and NSAID exposure.
- 05
Medication reconciliation and interaction review - Why
- Identify CYP3A4 inducers or inhibitors, glucose-lowering drugs, anticoagulants, live vaccines and medicines that compound toxicity.
- Interpretation and limitations
- The product SmPC describes dexamethasone as a moderate CYP3A4 inducer and notes bidirectional interaction with coumarin anticoagulants; monitoring and specialist pharmacy advice may be required.
- 06
Adrenal-axis assessment when clinically indicated - Why
- Evaluate possible suppression during or after prolonged treatment and distinguish withdrawal from neurological relapse.
- Interpretation and limitations
- Do not delay emergency glucocorticoid treatment for testing when adrenal crisis is suspected. Planned testing and taper follow duration, dose, symptoms and endocrine advice.
04Treatment approachPreparation, options, escalation and aftercare.
01Symptom-led dexamethasone pathwayAdult tumour with oedema-related focal deficitFirst stepAn adult has a brain tumour, radiological vasogenic oedema and progressive focal symptoms without immediate herniation.+
- 1DefinitiveDocument the neurological baseline, exclude haemorrhage, hydrocephalus, active seizure and infection, and contact the tumour team to link symptom control to definitive treatment.
- 2Start the lowest effective dexamethasone dose using the applicable product and neuroscience protocol; adult metastatic guidance considers 4–8 mg/day for mild symptoms and higher doses around 16 mg/day for severe mass-effect symptoms.
- 3EscalationReview clinical response and toxicity promptly rather than treating MRI appearance alone; escalate emergency care if consciousness, pupils or motor function worsens.
- 4As surgery, radiotherapy or systemic treatment controls the cause, taper as rapidly as clinically tolerated while watching for recurrent focal symptoms and adrenal withdrawal.
- 5Document dose, planned review, glucose and infection monitoring, and who owns the taper so treatment is not continued indefinitely by default.
02Different emergency pathwayPituitary apoplexy with cortisol riskA sellar lesion presents with sudden headache, severe visual loss, ophthalmoplegia, hypotension or altered consciousness.+
- 1Activate joint endocrine–neurosurgical emergency care and obtain cortisol and pituitary samples only if this does not delay treatment.
- 2Give empirical adult hydrocortisone when Society for Endocrinology criteria are present; do not substitute a tumour-oedema dexamethasone schedule.
- 3Obtain urgent pituitary MRI or pituitary CT if necessary and continue visual, haemodynamic and electrolyte assessment.
03Toxicity and taper pathwayImproving patient after definitive treatmentDefinitiveNeurological symptoms improve after surgery or radiotherapy and dexamethasone exposure can now be reduced.+
- 1Review the current dose, duration, neurological baseline, glucose, infection, mood, sleep and proximal strength and confirm who owns the taper.
- 2Reduce toward the lowest effective dose and stop as rapidly as clinically tolerated, slowing when substantial prior exposure creates adrenal-withdrawal risk.
- 3EscalationIf symptoms recur, distinguish the original focal oedema syndrome from diffuse withdrawal, tumour progression, haemorrhage, hydrocephalus or treatment effect before committing to long-term re-escalation.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Dexamethasone
For adults with metastatic-brain-tumour symptoms, CNS guidance considers 4–8 mg/day for mild mass-effect symptoms and about 16 mg/day or more for moderate to severe symptoms. Separately, one current UK 4 mg-tablet SmPC gives 6–16 mg/day orally, up to 24 mg/day, in 3–4 divided doses for cerebral oedema; use the applicable product and specialist protocol.Use the lowest effective dose and taper as rapidly as clinically tolerated. Monitor glucose, infection, mood, sleep, blood pressure, gastrointestinal risk and proximal strength; prolonged exposure causes adrenal suppression, osteoporosis and opportunistic infection. Review CYP3A4 and anticoagulant interactions. Do not generalise adult metastatic dosing to children or use it as pituitary-apoplexy adrenal replacement.
Hydrocortisone (distinct apoplexy indication)
In adult pituitary apoplexy meeting empirical-steroid criteria: 100 mg IM then 50–100 mg IM every 6 hours, or 100–200 mg IV then 2–4 mg/hour by continuous infusion, under endocrine–neurosurgical care.Treat without waiting for cortisol in haemodynamic instability, altered consciousness, reduced acuity or severe field defects. Monitor haemodynamics, glucose, sodium and fluid balance and obtain endocrine follow-up.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Record the indication, starting dose, neurological baseline, intended review date and named taper owner each time dexamethasone is prescribed.
- Check neurological function and symptom response early; new decline triggers urgent imaging for haemorrhage, hydrocephalus, progression or treatment effect.
- Monitor glucose, infection, mood and sleep, blood pressure, dyspepsia or bleeding, proximal strength and mobility in proportion to dose and duration.
- During taper, distinguish return of focal oedema symptoms from diffuse adrenal-withdrawal symptoms and adjust only after clinical review.
- For longer courses, address bone protection, opportunistic-infection risk and adrenal-suppression education through local specialist protocols.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Oedema response is not tumour response
A dramatic improvement after dexamethasone reflects reduced vascular permeability and pressure; the underlying tumour may be unchanged.
Dose belongs to population
The 4–8 and 16 mg guidance is for symptomatic adults with brain metastases, while an SmPC dose is product-specific; neither creates a universal paediatric or primary-tumour regimen.
Possible lymphoma needs thought
Glucocorticoids can shrink or alter CNS lymphoma before biopsy. When clinically safe, involve the specialist team before exposure; life-threatening mass effect still takes priority.
Myopathy mimics decline
Symmetric proximal weakness and loss of chair-rise ability can be steroid toxicity rather than a new focal tumour deficit.
Every course needs an exit
A prescription without a review and taper plan commonly becomes unnecessary long-term exposure.
08Common pitfallsFrequent interpretation and management errors.
- 01
Starting dexamethasone solely for an asymptomatic imaging abnormality without a clinical indication.
- 02
Applying adult metastatic dose recommendations to children or every primary brain tumour.
- 03
Continuing high-dose dexamethasone while delaying urgent neurosurgical control of hydrocephalus or haemorrhage.
- 04
Stopping a prolonged course abruptly or allowing it to continue indefinitely without a named taper owner.
- 05
Using dexamethasone for vasogenic oedema as a substitute for hydrocortisone in pituitary apoplexy with adrenal failure.